Bruton's Tyrosine Kinase Inhibition in Multiple Sclerosis.

Curr Neurol Neurosci Rep

Division of Neurology, Department of Medicine, St Michael's Hospital, Unity Health, University of Toronto, 30 Bond St, PGT 17-742, Toronto, ON, M5B 1W8, Canada.

Published: November 2022

Purpose Of Review: Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) with a chronic and often progressive disease course. The current disease-modifying treatments (DMTs) limit disease progression primarily by dampening immune cell activity in the peripheral blood or hindering their migration from the periphery into the CNS. New therapies are needed to target CNS immunopathology, which is a key driver of disability progression in MS. This article reviews Bruton's Tyrosine Kinase Inhibitors (BTKIs), a new class of experimental therapy that is being intensely evaluated in MS. We focus on the potential peripheral and central mechanisms of action of BTKIs and their use in recent clinical trials in MS.

Recent Findings: There is evidence that some BTKIs cross the blood-brain barrier and may be superior to currently available DMTs at dampening the chronic neuroinflammatory processes compartmentalized within the CNS that contribute to progressive worsening in people withMS (pwMS). Recently, evobrutinib and tolebrutinib have shown efficacy in phase II clinical trials, and there are numerous ongoing phase III clinical trials of various BTKIs in relapsing and progressive forms of MS. Results from these clinical trials will be essential to understand the efficacy and safety of BTKIs across the spectrum of MS and keydifferences between specific BTKIs when treating pwMS. Inhibition of BTK has emerged as an attractive strategy to target cells of the adaptive and innate immune system outside and within the CNS. BTKIs carry great therapeutic potential across the MS spectrum, where key pathobiology aspects seem confined to the CNS compartment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607648PMC
http://dx.doi.org/10.1007/s11910-022-01229-zDOI Listing

Publication Analysis

Top Keywords

clinical trials
16
bruton's tyrosine
8
tyrosine kinase
8
multiple sclerosis
8
system cns
8
btkis
7
cns
6
kinase inhibition
4
inhibition multiple
4
sclerosis purpose
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!